Johnson & Johnson (NYSE:JNJ) Shares Acquired by OmniStar Financial Group Inc.

OmniStar Financial Group Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 10.8% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,163 shares of the company’s stock after buying an additional 896 shares during the quarter. Johnson & Johnson accounts for about 1.2% of OmniStar Financial Group Inc.’s portfolio, making the stock its 18th largest holding. OmniStar Financial Group Inc.’s holdings in Johnson & Johnson were worth $1,339,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in JNJ. GUNN & Co INVESTMENT MANAGEMENT INC. increased its holdings in shares of Johnson & Johnson by 1,194.9% in the fourth quarter. GUNN & Co INVESTMENT MANAGEMENT INC. now owns 237,273 shares of the company’s stock valued at $37,190,000 after purchasing an additional 218,949 shares during the last quarter. Wynn Capital LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at $1,910,000. Capital Advisors Ltd. LLC increased its stake in shares of Johnson & Johnson by 6.4% in the 4th quarter. Capital Advisors Ltd. LLC now owns 3,454 shares of the company’s stock worth $541,000 after acquiring an additional 209 shares during the last quarter. Atria Wealth Solutions Inc. raised its holdings in shares of Johnson & Johnson by 2.8% during the 4th quarter. Atria Wealth Solutions Inc. now owns 162,847 shares of the company’s stock worth $25,525,000 after acquiring an additional 4,497 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in shares of Johnson & Johnson by 2.4% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 56,732 shares of the company’s stock valued at $8,892,000 after acquiring an additional 1,343 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. TD Securities reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Morgan Stanley lifted their target price on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Finally, TD Cowen reduced their price target on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $173.21.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $164.23 on Friday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $165.83. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market cap of $395.25 billion, a P/E ratio of 10.24, a PEG ratio of 2.63 and a beta of 0.52. The firm has a fifty day moving average price of $155.01 and a 200 day moving average price of $153.38.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.80 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.